Receive instant alerts when news is published about your stocks. Claim your one week free trial for StreetInsider Premium here.
CAMBRIDGE, Mass.–(BUSINESS WIRE)–
Therapeutic caraway announced today that the Company will participate in two upcoming investor conferences.
Caraway CEO Martin D. Williams will present recent advances in the company’s TRPML1 program at the Fall Life Sciences Private Company Showcase, co-hosted by BMO Capital Markets, Solebury Strategic Communications and Goodwin in New York City, NY on October 13, 2022, from 4:20 p.m. to 4:40 p.m. ET.
Williams will also present at the Oppenheimer Private Company Showcase in Palo Alto, Calif., on October 18, 2022, from 9:25 a.m. to 9:45 a.m. PT.
“I look forward to sharing the latest updates on Caraway’s work to develop precision drugs for CNS and rare diseases,” Williams said. “We continue to advance our TRPML1 program for GBA-Parkinson’s disease and other rare genetic diseases and look forward to discussing our progress with investors.”
About Caraway Therapeutics
Caraway Therapeutics is a biopharmaceutical company pursuing novel approaches for the treatment of genetically defined neurodegenerative and rare diseases. The company is a leader in the cutting-edge science of activating cellular recycling processes to remove toxic materials and defective cellular components by modulating lysosomal function. Caraway uses its unique product engine to develop proprietary insights into lysosomal function and small molecule ion channel modulation and advance a robust pipeline of precision therapeutic candidates with disease-modifying potential for patients. The company is backed by leading investors including SV Health Investors, AbbVie Ventures, MRLV Fund, Amgen Ventures, Dementia Discovery Fund, Alexandria Venture Investments and Eisai Innovation.
Caraway is based in Cambridge, MA. For more information, please visit www.carawaytx.com.
Kari Watson or Carolyn Noyes
[email protected] Where [email protected]
Source: Caraway Therapeutics